Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab.

Canakinumab is a human monoclonal antibody anti-interleukin-l beta, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.